Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
Gene & Mutation Overview
CTAG2 (Cancer/Testis Antigen 2, also known as LAGE-1) is a cancer-testis antigen encoded by the CTAG2 gene (UniProt O75638). Known mutations include dbSNP:rs17855367 (VAR_007855), dbSNP:rs17328091 (VAR_007856), and dbSNP:rs5987003 (VAR_057512), which may influence epitope presentation in certain HLA haplotypes.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTAG2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTAG2 Recombinant Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. E. coli or HEK293 Expressed. |
View CTAG2 Products |
| Gene Delivery | CTAG2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for TCR-T target cell construction. Titers >10⁸ TU/mL. |
View CTAG2 Products |
| Benchmark Ab | Anti-CTAG2 Monoclonal Antibody (Clone E978) Research-grade positive control for expression verification. |
View CTAG2 Products |
| Validator | CTAG2 siRNA Set (3 Target-Specific + 1 Control) For knockdown verification and specificity checks. |
View CTAG2 Products |
| Related Target: CTAG1B | NY-ESO-1 (CTAG1B) High homology paralog; critical for cross-reactivity counter-screening. |
View CTAG1B Products |
| Related Target: HLA-A | MHC Class I component crucial for CTAG2 peptide presentation to TCRs. | View HLA-A Products |
| Related Target: MAGEA4 | MAGE-A4 Synergistic cancer-testis antigen for multi-target TCR strategies. |
View MAGEA4 Products |
| Related Target: PRAME | Preferentially Expressed Antigen in Melanoma (PRAME) Alternative CT antigen for heterogeneity coverage. |
View PRAME Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening (CTAG1B/NY-ESO-1) | Homolog panel proteins (CTAG2 and CTAG1B) rigorously sequence verified and high purity (>95%) |
| Target Cell Line Generation for TCR-T | Lentivirus Premade Particles for stable integration and reliable antigen presentation |
| Lack of Controls for Expression | Recombinant Benchmark Antibodies included for precise assay calibration |
| False Positives in Efficacy Assays | Validated siRNA included for strict specificity checks in cell-based assays |
| MHC presentation validation (TCR-T development) | Lentivirus particles for stable HLA-A*02:01+ cell line construction; Native conformation preservation |
| Preclinical species cross-reactivity | Human/Mouse CTAG2 ortholog proteins available; Theoretical MW verified |
Live CTAG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Immunotherapy Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for CTAG2 (LAGE-1) therapeutics is intensifying, with major players shifting focus from traditional approaches to TCR-T cell therapies and personalized cancer vaccines. Because CTAG2 is an intracellular cancer/testis antigen, it must be presented by HLA molecules. The field recognizes CTAG2 as a distinct target from its paralog CTAG1B (NY-ESO-1), due to non-overlapping HLA-presented epitopes in many haplotypes. As first-generation therapies reach the clinic, the next wave of R&D is targeting TCR-mimic bispecific antibodies, dual-targeting CAR-T cells, and combination checkpoint inhibition strategies to overcome tumor heterogeneity, HLA down-regulation, and tumor microenvironment suppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Adaptimmune, Immatics, TCR² Therapeutics | Melanoma, Synovial Sarcoma, Myeloma | Target Cell Generation (Need Lentivirus for stable expression) |
| Cancer Vaccines | Moderna, BioNTech | Solid Tumors, Bladder Cancer, NSCLC | Immunogenicity Testing (Need High-purity recombinant proteins) |
| TCR-Mimic Bispecifics | Immunocore, Cue Biopharma | Refractory Solid Tumors (HLA-A2+) | Selectivity Assay (Need CTAG1B counter-screen proteins) |
| CAR-T (TCR-mimic) | Precision Biosciences, Eureka Therapeutics | Hematologic Malignancies | Cell line construction (Need Lentivirus for antigen-positive target cells) |